GSK's Tafinlar named as FDA breakthrough therapy for lung cancer
LONDON (Reuters) - British pharmaceutical company GlaxoSmithKline said its Tafinlar cancer treatment had been given FDA breakthrough therapy designation for lung cancer, meaning the drug will be fast-tracked within the U.S. regulatory system.
GSK said that Tafinlar, also known as dabrafenib, was designated an FDA breakthrough therapy on Monday following interim results from an ongoing Phase II study.
Tafinlar is already approved for melanoma, the deadliest form of skin cancer.
(Reporting by Sarah Young, Editing by Paul Sandle)
- EU and U.S. announce new sanctions on Russia over Ukraine |
- U.S. Senate bill proposes sweeping curbs on NSA surveillance
- At least 43 Palestinians killed as Israel maintains pressure on Gaza |
- Putin may have passed point of no-return over Ukraine
- Water main break, geyser flood UCLA campus, strand motorists |